Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties

被引:11
|
作者
Ma, Lichun [1 ]
Wang, Debby D. [1 ]
Huang, Yiqing [2 ]
Wong, Maria P. [3 ]
Lee, Victor H. F. [3 ]
Yan, Hong [1 ]
机构
[1] City Univ Hong Kong, Dept Elect Engn, Kowloon, Hong Kong, Peoples R China
[2] Soochow Univ, Sch Comp Sci & Technol, Suzhou, Peoples R China
[3] Univ Hong Kong, Li Ka Sing Fac Med, Pokfulam, Hong Kong, Peoples R China
关键词
Drug resistance; EGFR mutation; Lung cancer; Alpha shape; Solid angle; Protein surface geometric properties; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; GEFITINIB; PREDICTION; DESIGN; ASSOCIATION; TUMORS;
D O I
10.1016/j.compbiomed.2014.06.016
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Epidermal growth factor receptor (EGFR) mutation-induced drug resistance leads to a limited efficacy of tyrosine kinase inhibitors during lung cancer treatments. In this study, we explore the correlations between the local surface geometric properties of EGFR mutants and the progression-free survival (PFS). The geometric properties include local surface changes (four types) of the EGFR mutants compared with the wild-type EGER, and the convex degrees of these local surfaces. Our analysis results show that the Spearman's rank correlation coefficients between the PFS and three types of local surface properties are all greater than 0.6 with small P-values, implying a high significance. Moreover, the number of atoms with solid angles in the ranges of [0.71,1], [0.61,1] or [10.5, 1], indicating the convex degree of a local EGFR surface, also shows a strong correlation with the PFS. Overall, these characteristics can be efficiently applied to the prediction of drug resistance in lung cancer treatments, and easily extended to other cancer treatments. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 300
页数:8
相关论文
共 50 条
  • [21] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Bell, DW
    Gore, I
    Okimoto, RA
    Godin-Heymann, N
    Sordella, R
    Mulloy, R
    Sharma, SV
    Brannigan, BW
    Mohapatra, G
    Settleman, J
    Haber, DA
    NATURE GENETICS, 2005, 37 (12) : 1315 - 1316
  • [22] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Daphne W Bell
    Ira Gore
    Ross A Okimoto
    Nadia Godin-Heymann
    Raffaella Sordella
    Roseann Mulloy
    Sreenath V Sharma
    Brian W Brannigan
    Gayatry Mohapatra
    Jeff Settleman
    Daniel A Haber
    Nature Genetics, 2005, 37 : 1315 - 1316
  • [23] Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem
    Hao, Ge-Fei
    Yang, Guang-Fu
    Zhan, Chang-Guo
    DRUG DISCOVERY TODAY, 2012, 17 (19-20) : 1121 - 1126
  • [24] Virus-like Plasmonic Nanoprobes for Quick Analysis of Antiviral Efficacy and Mutation-Induced Drug Resistance
    Ouyang, Yuzhi
    Chen, Yancao
    Shang, Jinhui
    Sun, Shijie
    Wang, Xiangbin
    Huan, Shuangyan
    Xiong, Bin
    Zhang, Xiao-Bing
    ANALYTICAL CHEMISTRY, 2023, 95 (11) : 5009 - 5017
  • [25] EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Haneda, Hiroshi
    Suzuki, Eriko
    Yukiue, Haruhiro
    Kobayashi, Yoshihiro
    Yano, Motoki
    Fujii, Yoshitaka
    CANCER RESEARCH, 2006, 66 (08)
  • [26] Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
    Dienstmann, Rodrigo
    De Dosso, Sara
    Felip, Enriqueta
    Tabernero, Josep
    MOLECULAR ONCOLOGY, 2012, 6 (01) : 15 - 26
  • [27] Diaphragmatic hernia during treatment of lung cancer harboring an EGFR mutation
    Konno-Yamamoto, Aya
    Narumoto, Osamu
    Yamamoto, Shota
    Yamaguchi, Miho
    Motoyoshi, Makoto
    Inoue, Yuta
    Fukami, Takeshi
    Tamura, Atsuhisa
    Matsui, Hirotoshi
    OXFORD MEDICAL CASE REPORTS, 2021, (07): : 263 - 265
  • [28] EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer
    Sasaki, H
    Endo, K
    Mizuno, K
    Yano, M
    Fukai, I
    Yamakawa, Y
    Fujii, Y
    LUNG CANCER, 2006, 51 (01) : 135 - 136
  • [29] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
  • [30] Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
    Tsubata, Yukari
    Tanino, Ryosuke
    Isobe, Takeshi
    CELLS, 2021, 10 (11)